The birth of a biotech startup

Dr. Aznarez and Professor Krainer recognized that their insights on RNA splicing and RNA metabolism pathways could potentially be translated into medicines to improve the lives of people living with serious diseases. Teaming up with Dr. Nash, the three founded Stoke Therapeutics. Backed by a veteran leadership team and $40 million from Apple Tree Partners, Stoke emerged from stealth mode in January 2018. Stoke subsequently added $90 million in Series B financing from a syndicate of investors in October 2018.